Fortress Biotech, Inc. (FBIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.90
- As of
Kresmion compiles this page from FBIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Fortress Biotech, Inc. (FBIO): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
See the full FBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for FBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the FBIO dossierActive signals for FBIO
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 60.8%, EPS $-0.08 vs $-0.204 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 403.6% - EPS $-1.13 vs $-0.2244 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 36.2% - EPS $-0.5 vs $-0.3672 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 125.7% - EPS $0.11 vs $-0.4284 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 108.9% - EPS $-0.01 vs $0.1122 estimate
FREE, NO ACCOUNT
Every signal on FBIO, as it fires
New filings, 13F moves and cross asset signals on FBIO land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FBIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 34960Q307 · 2026Q2 | $654K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 34960Q307 · 2026Q2 | $264K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 34960Q307 · 2026Q2 | $236K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FBIO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
FBIO against its peers
FBIO's operating margin of -111.0% ranks in the 35th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-04-30.
| Metric | FBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 63.3M USD | 2.2M USD | 88 | 12 |
| Operating margin | -111.0% | -76.0% | 35 | 9 |
| Net margin | 10.8% | -75.8% | 85 | 9 |
| Return on equity | 13.7% | -73.4% | 92 | 17 |
| 1 year | -30.4% | -26.1% | 38 | 19 |
Peers (22): HRTX, CSBR, RNTX, NMRA, RNXT, XBIT, SPRO, CING, KLRS, INKT, MAIA, GANX, MNOV, ELOX, VRCA, ACET, AURX, OSTX, BOLD, TENX, NTHI, XLO. Left out: APLM (period gap), HYFT (period gap), OKYO (period gap). Fiscal periods ending between 2025-12-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (FBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow FBIO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to FBIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.